Autonomic Stress Modulation by Nutraceutical, Microbiota-Directed, and Sensory Agents: An Evidence Synthesis with Pathway Map

Autonomic stress modulation by nutraceutical, microbiota-directed and sensory agents

A PRISMA-aligned evidence synthesis with a 50-substance pathway map

No substance in this evidence base should be described as a proven, general-purpose “parasympathetic activator.” HRV is an indirect measure of cardiac autonomic regulation.[1] The review framework labels cardiac-vagal indices, stress physiology, and symptom scores as separate outcome tiers. In the clearest dietary RCT located, almonds increased high-frequency HRV during a mental-stress task but not other HRV indices, illustrating why the review treats signals as context-specific rather than as global vagal activation.[1]

Figure 1. Flow diagram for the completed review. The analysis will retain the 265 reports not retrieved as a distinct PRISMA category rather than treating them as ineligible.

Methods and evidence hierarchy

The completed review screened 882 records, sought 515 reports for retrieval, and retained 243 reports after full-text screening. The PRISMA figure keeps non-retrieval separate from eligibility exclusions. Before quantitative conclusions are finalised, multiple reports from the same randomised cohort must be collapsed into a trial family; the 50-row table below is therefore a substance-level evidence map, not a meta-analysis.[2]

The hierarchy is: direct autonomic evidence (controlled RMSSD, HF-HRV, PEP, RSA or comparable cardiac-vagal measures); indirect stress physiology (cortisol, alpha-amylase, GSR, catecholamines); then patient-reported outcomes. A lower-tier endpoint cannot establish parasympathetic activation. In the almond trial, HF power is explicitly interpreted as a parasympathetic respiratory-modulation measure, whereas LF/HF has contested physiological meaning.[1]

Figure 2. Report-level map of the completed review. Each included report was coded from its extracted route and ingredient identity and by whether it reported a direct autonomic biomarker, indirect stress physiology only, or symptoms/other outcomes only. Cell values are report counts, not effect direction, certainty, or independent trial counts; trial-family deduplication will precede quantitative synthesis.

Candidate mechanistic framework

Figure 3. Conceptual framework for the review. Arrows denote biologically plausible candidate routes, not demonstrated mediation in the included trials. The paper will distinguish mechanistic rationale from clinical evidence of changes in autonomic or stress biomarkers.

The diagram is intentionally a candidate-pathway framework. Controlled trials can demonstrate a biomarker change but rarely establish that a proposed olfactory, vagal-afferent, immune-metabolic, or HPA-axis route mediated it. For example, the almond investigators list several possible nutrient, vascular, baroreflex, glycaemic, and stress-related explanations rather than identifying one mechanism.[1]

Master 50-substance evidence map

Interpretation rule: “Direct” means that at least one controlled human report evaluated a cardiac-autonomic measure; it does not mean replicated efficacy. “Indirect” means the reviewed human evidence was chiefly neuroendocrine, electrodermal, EEG, or symptom-level. “Candidate pathway” is a mechanistic hypothesis, not a confirmed mediator. EU status must be verified ingredient-by-ingredient and must not be converted into an autonomic health claim. This classification rule follows the evidence hierarchy applied in this paper rather than asserting authorisation or efficacy. The distinction between HF/RMSSD and LF/HF interpretation is grounded in the HRV measurement discussion of the controlled almond trial.[1]

Evidence-weighted interpretation

The table is deliberately not a product-ranking list. The strongest question for each candidate is whether a placebo- or control-comparative change in RMSSD, HF-HRV, RSA or PEP is replicated in a population and context relevant to intended use. The direct evidence that appears in one small, acute sensory study or in a multi-ingredient formulation should not be transported into a consumer-level autonomic claim. The next manuscript step is a trial-family audit, followed by effect-size extraction only where the underlying reports supply compatible means, dispersions, timepoints, and comparators. The need to deduplicate report-level evidence before quantitative synthesis is explicit in the review-flow audit.[2]

Figures from source document